These are slides, we'll be including to the ppt:- 1. Title Slide & Introduction 2.Objectives 3.Guideline Development Working Groups. 4. Methods 5. Clinical Practice Guidelines:- 5.1 Defination & Diagnosis Of Asthma 5.2 Recognizing & Managing acute exacerbations 5.3 Principles of Long term Management in Asthma 5.4 Education and Prevention of Asthma 5.5 Risk Evaluation 6.Summary 7. Refrences 8.Ending Slide.. these are the topic in slides of ppt .. my topic is just 5.3 so give me answers accordingly to the given ppt for 5.3 sections .. provide me content for 5 to 8 slides just from the given pdf.. make a slide content in simple understandable .. make me ppt also so I use it as reference for a canva which I gonna make
cd /home/daytona/workspace/attachments/049331ca-3c33-4474-80c8-d1c42adc7e22 && pβ¦
cd /home/daytona/workspace/attachments/049331ca-3c33-4474-80c8-d1c42adc7e22 && pβ¦
cd /home/daytona/workspace/attachments/049331ca-3c33-4474-80c8-d1c42adc7e22 && pβ¦
mkdir -p /home/daytona/workspace/asthma-ppt && ls /home/daytona/workspace/asthmaβ¦
~/asthma-ppt/build.js
const pptxgen = require("pptxgenjs");
let pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.title = "5.3 Principles of Long-Term Management in Asthma";
// βββ THEME COLORS ββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ
const NAVY = "0D2F5C"; // dominant dark background
const TEAL = "00A89D"; // accent / headers
const WHITE = "FFFFFF";
const LTBLUE = "E8F4F8"; // light panel bg
const GRAY = "B0BEC5"; // sub-text
const ORANGE = "F57C00"; // highlight accent
// βββ HELPER: add a slide header bar βββββββββββββββββββββββββββββββββββββββββ
function addHeader(slide, title, sub) {
// top navy bar
slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 1.1, fill: { color: NAVY }, line: { color: NAVY } });
// teal left stripe
slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 0.18, h: 1.1, fill: { color: TEAL }, line: { color: TEAL } });
slide.addText(title, { x: 0.3, y: 0.12, w: 9.5, h: 0.6, fontSize: 22, bold: true, color: WHITE, fontFace: "Calibri", margin: 0 });
if (sub) {
slide.addText(sub, { x: 0.3, y: 0.7, w: 9.5, h: 0.35, fontSize: 11, color: TEAL, fontFace: "Calibri", margin: 0, italic: true });
}
// navy footer bar
slide.addShape(pres.ShapeType.rect, { x: 0, y: 5.35, w: 10, h: 0.28, fill: { color: NAVY }, line: { color: NAVY } });
slide.addText("5.3 Principles of Long-Term Management in Asthma | Clinical Practice Guidelines", {
x: 0.2, y: 5.36, w: 9.5, h: 0.24, fontSize: 8, color: GRAY, fontFace: "Calibri", margin: 0
});
}
// βββ SLIDE 1: SECTION TITLE ββββββββββββββββββββββββββββββββββββββββββββββββββ
{
let s = pres.addSlide();
// full navy bg
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: NAVY }, line: { color: NAVY } });
// teal accent band
s.addShape(pres.ShapeType.rect, { x: 0, y: 2.2, w: 10, h: 0.08, fill: { color: TEAL }, line: { color: TEAL } });
// section tag
s.addText("SECTION 5.3", { x: 0.6, y: 1.0, w: 9, h: 0.5, fontSize: 14, bold: true, color: TEAL, fontFace: "Calibri", align: "left", margin: 0 });
// main title
s.addText("Principles of Long-Term\nManagement in Asthma", {
x: 0.6, y: 1.5, w: 8.8, h: 1.6, fontSize: 36, bold: true, color: WHITE, fontFace: "Calibri", align: "left", margin: 0
});
// subtitle
s.addText("Pharmacologic Management Β· Step Therapy Β· Step-Down Β· Referral Β· Self-Management", {
x: 0.6, y: 3.1, w: 9, h: 0.5, fontSize: 13, color: GRAY, fontFace: "Calibri", align: "left", margin: 0
});
// source tag
s.addText("Source: Philippine Clinical Practice Guidelines on the Diagnosis & Management of Asthma (Chapter 3)", {
x: 0.6, y: 4.9, w: 9, h: 0.35, fontSize: 9, color: GRAY, fontFace: "Calibri", align: "left", margin: 0, italic: true
});
}
// βββ SLIDE 2: OVERVIEW OF LONG-TERM MANAGEMENT βββββββββββββββββββββββββββββββ
{
let s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LTBLUE }, line: { color: LTBLUE } });
addHeader(s, "Overview: Long-Term Asthma Management", "Chapter 3 β Key Components");
const boxes = [
{ label: "π Pharmacologic\nManagement", desc: "ICS, ICS-LABA, SABA relievers\n(Key Question 4)", x: 0.3, y: 1.3 },
{ label: "πΏ Non-Pharmacologic\nStrategies", desc: "Prevention, trigger avoidance\n(Key Questions 6, 7, 8)", x: 3.55, y: 1.3 },
{ label: "π Self-Management\n& Education", desc: "Written Asthma Action Plan\n(Key Question 5)", x: 6.8, y: 1.3 },
];
boxes.forEach(b => {
s.addShape(pres.ShapeType.rect, { x: b.x, y: b.y, w: 3.05, h: 1.8, fill: { color: NAVY }, line: { color: TEAL, pt: 2 }, rounding: 0.1 });
s.addText(b.label, { x: b.x + 0.1, y: b.y + 0.1, w: 2.85, h: 0.8, fontSize: 13, bold: true, color: TEAL, fontFace: "Calibri", align: "center", margin: 0 });
s.addText(b.desc, { x: b.x + 0.1, y: b.y + 0.9, w: 2.85, h: 0.8, fontSize: 11, color: WHITE, fontFace: "Calibri", align: "center", margin: 0 });
});
s.addText("Key Principle:", { x: 0.4, y: 3.3, w: 1.6, h: 0.35, fontSize: 12, bold: true, color: ORANGE, fontFace: "Calibri", margin: 0 });
s.addText("A strong partnership with effective communication between patients, families, and healthcare providers is essential across all components.", {
x: 0.4, y: 3.65, w: 9.2, h: 0.6,
fontSize: 12, color: NAVY, fontFace: "Calibri", italic: true, margin: 0
});
s.addText("Additionally: Indications for specialist referral and management of difficult-to-treat asthma are also covered in this section.", {
x: 0.4, y: 4.3, w: 9.2, h: 0.5,
fontSize: 11, color: NAVY, fontFace: "Calibri", margin: 0
});
}
// βββ SLIDE 3: PHARMACOLOGICAL MANAGEMENT βββββββββββββββββββββββββββββββββββββ
{
let s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LTBLUE }, line: { color: LTBLUE } });
addHeader(s, "Pharmacological Management", "Section 11 β Categories & Step Therapy");
// 3 categories
const cats = [
{ title: "1. Controller\n(Maintenance)", color: NAVY, items: ["Reduce airway inflammation", "Control symptoms", "Decrease future risks", "Examples: ICS, ICS-LABA"] },
{ title: "2. Reliever\n(Rescue)", color: "1A5276", items: ["Provided to ALL patients", "As-needed symptom relief", "For acute exacerbations", "Example: SABA"] },
{ title: "3. Add-on\n(Adjunct)", color: "145A32", items: ["For uncontrolled asthma", "Despite high-dose therapy", "Examples: Biologics, LAMA", "Refer to specialist"] },
];
cats.forEach((c, i) => {
let x = 0.25 + i * 3.2;
s.addShape(pres.ShapeType.rect, { x, y: 1.2, w: 3.0, h: 0.55, fill: { color: c.color }, line: { color: c.color } });
s.addText(c.title, { x: x + 0.05, y: 1.22, w: 2.9, h: 0.5, fontSize: 11, bold: true, color: WHITE, fontFace: "Calibri", align: "center", margin: 0 });
s.addShape(pres.ShapeType.rect, { x, y: 1.75, w: 3.0, h: 1.9, fill: { color: WHITE }, line: { color: c.color, pt: 1.5 } });
c.items.forEach((item, j) => {
s.addText([{ text: "β’ " + item }], { x: x + 0.1, y: 1.8 + j * 0.45, w: 2.8, h: 0.42, fontSize: 10.5, color: "333333", fontFace: "Calibri", margin: 0 });
});
});
s.addText("Step-Up / Step-Down Philosophy:", { x: 0.35, y: 3.85, w: 3.2, h: 0.32, fontSize: 11, bold: true, color: ORANGE, fontFace: "Calibri", margin: 0 });
const steps = [
"Review response within 1β3 months; then every 3β12 months",
"Step-up if uncontrolled; step-down once stable for β₯3 months",
"Any step change is a therapeutic trial β monitor closely",
"After exacerbation: follow-up within 1 week"
];
steps.forEach((t, i) => {
s.addText([{ text: "βΈ " + t }], { x: 0.35, y: 4.2 + i * 0.26, w: 9.3, h: 0.25, fontSize: 10, color: NAVY, fontFace: "Calibri", margin: 0 });
});
}
// βββ SLIDE 4: STEP THERAPY BY AGE ββββββββββββββββββββββββββββββββββββββββββββ
{
let s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LTBLUE }, line: { color: LTBLUE } });
addHeader(s, "Step Therapy by Age Group", "Section 11.2 β Treatment Tracks (Adapted from GINA 2021)");
const rows = [
["Age Group", "Step 1 (Mild)", "Step 2 (Moderate)", "Step 3β4 (Uncontrolled)", "Step 5 (Severe)"],
["<6 years", "Low dose ICS\n+ as-needed SABA", "Low dose ICS daily\n+ as-needed SABA", "Medium dose ICS\nor ICS-LABA", "Refer to specialist"],
["6β11 years", "Low dose ICS\nwhen SABA taken", "Daily low dose ICS\n+ as-needed SABA", "Low dose ICS-LABA\n(SMART option)", "Medium dose ICS-LABA\n+ as-needed SABA"],
["12β18 years\n(Track 1)", "As-needed low dose\nICS-formoterol", "As-needed low dose\nICS-formoterol", "Low dose ICS-LABA\nmaintenance + reliever", "Medium dose ICS-LABA\n+ consider add-on"],
["12β18 years\n(Track 2)", "Low dose ICS\nwhen SABA taken", "Daily low dose ICS\n+ as-needed SABA", "Low-medium dose ICS\n+ LABA + SABA", "Medium-high ICS-LABA\n+ LAMA/OCS"],
];
const colW = [1.5, 1.9, 2.0, 2.3, 2.1];
const colX = [0.1, 1.65, 3.6, 5.65, 8.0];
const rowH = 0.72;
const rowY = [1.15, 1.87, 2.6, 3.33, 4.06];
rows.forEach((row, ri) => {
row.forEach((cell, ci) => {
const isHeader = ri === 0;
const isRowHead = ci === 0 && ri > 0;
const bg = isHeader ? NAVY : isRowHead ? "1A3A5C" : (ri % 2 === 0 ? "EAF4F8" : WHITE);
const fc = (isHeader || isRowHead) ? WHITE : "222222";
s.addShape(pres.ShapeType.rect, { x: colX[ci], y: rowY[ri], w: colW[ci], h: rowH, fill: { color: bg }, line: { color: TEAL, pt: 0.5 } });
s.addText(cell, { x: colX[ci] + 0.05, y: rowY[ri] + 0.04, w: colW[ci] - 0.1, h: rowH - 0.08, fontSize: 8.5, color: fc, fontFace: "Calibri", align: "center", valign: "middle", margin: 0, bold: isHeader });
});
});
s.addText("SMART = Single Maintenance And Reliever Therapy | SABA = Short-Acting Beta-2 Agonist | ICS = Inhaled Corticosteroid | LABA = Long-Acting Beta-2 Agonist", {
x: 0.1, y: 4.95, w: 9.8, h: 0.22, fontSize: 7.5, color: "666666", fontFace: "Calibri", italic: true, margin: 0
});
}
// βββ SLIDE 5: STEP-DOWN STRATEGY βββββββββββββββββββββββββββββββββββββββββββββ
{
let s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LTBLUE }, line: { color: LTBLUE } });
addHeader(s, "When & How to Step Down Treatment", "Section 11.4 β Reducing Medications Safely");
// goal box
s.addShape(pres.ShapeType.rect, { x: 0.3, y: 1.2, w: 9.4, h: 0.55, fill: { color: NAVY }, line: { color: NAVY } });
s.addText("π― Goal: Find the patient's MINIMUM EFFECTIVE asthma treatment while keeping them symptom-free", {
x: 0.4, y: 1.22, w: 9.2, h: 0.48, fontSize: 12, bold: true, color: TEAL, fontFace: "Calibri", margin: 0
});
// trigger
s.addText("When can you step down?", { x: 0.3, y: 1.9, w: 4, h: 0.3, fontSize: 12, bold: true, color: ORANGE, fontFace: "Calibri", margin: 0 });
const trigger = [
"Good asthma control achieved for β₯3 months",
"Lung function significantly improved or plateaued",
"No respiratory infection, not pregnant, not travelling"
];
trigger.forEach((t, i) => {
s.addText([{ text: "β " + t }], { x: 0.4, y: 2.22 + i * 0.32, w: 4.5, h: 0.3, fontSize: 11, color: "145A32", fontFace: "Calibri", bold: true, margin: 0 });
});
// steps
s.addText("How to step down:", { x: 5.1, y: 1.9, w: 4.5, h: 0.3, fontSize: 12, bold: true, color: ORANGE, fontFace: "Calibri", margin: 0 });
const howTo = [
"Reduce ICS dose by 25β50% at 3-month intervals",
"Provide updated Written Asthma Action Plan (WAAP)",
"Identify risk factors before reducing (e.g., recent ER visit, low FEVβ)",
"Do NOT completely withdraw ICS β risk of exacerbation",
"Keep previous-dose medication available for emergencies",
"Monitor symptoms / PEF; schedule follow-up visit"
];
howTo.forEach((t, i) => {
s.addText([{ text: "βΈ " + t }], { x: 5.1, y: 2.22 + i * 0.32, w: 4.6, h: 0.3, fontSize: 10, color: NAVY, fontFace: "Calibri", margin: 0 });
});
// divider
s.addShape(pres.ShapeType.line, { x: 4.95, y: 1.85, w: 0, h: 2.5, line: { color: TEAL, pt: 1.5 } });
}
// βββ SLIDE 6: REFERRAL & DIFFICULT-TO-TREAT ASTHMA βββββββββββββββββββββββββββ
{
let s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LTBLUE }, line: { color: LTBLUE } });
addHeader(s, "Specialist Referral & Difficult-to-Treat Asthma", "Sections 12 & 13 β When to Refer | Severe Asthma");
// left panel β referral indications
s.addShape(pres.ShapeType.rect, { x: 0.2, y: 1.2, w: 4.6, h: 0.38, fill: { color: NAVY }, line: { color: NAVY } });
s.addText("π Indications for Specialist Referral", { x: 0.3, y: 1.22, w: 4.4, h: 0.33, fontSize: 11, bold: true, color: WHITE, fontFace: "Calibri", margin: 0 });
const referral = [
"Difficulty confirming asthma diagnosis",
"Suspected occupational or allergic asthma",
"Persistent/uncontrolled despite Step 4 treatment",
"Frequent ER or ICU visits / near-fatal attack",
"Anaphylaxis or confirmed food allergy + asthma",
"Significant side-effects of medications",
"Need for long-term oral corticosteroids",
"Growth delay (in children 6β11 years)"
];
referral.forEach((t, i) => {
s.addText([{ text: "β’ " + t }], { x: 0.3, y: 1.62 + i * 0.36, w: 4.4, h: 0.34, fontSize: 10, color: NAVY, fontFace: "Calibri", margin: 0 });
});
// right panel β difficult asthma
s.addShape(pres.ShapeType.rect, { x: 5.1, y: 1.2, w: 4.6, h: 0.38, fill: { color: "7B241C" }, line: { color: "7B241C" } });
s.addText("β Difficult-to-Treat & Severe Asthma", { x: 5.2, y: 1.22, w: 4.4, h: 0.33, fontSize: 11, bold: true, color: WHITE, fontFace: "Calibri", margin: 0 });
const difficult = [
"Uncontrolled on medium/high ICS + 2nd controller",
"Rule out first: poor inhaler technique (up to 80%)",
"Rule out first: poor adherence (up to 75%)",
"Rule out: incorrect diagnosis / comorbidities",
"Comorbidities: rhinosinusitis, GERD, obesity, OSA",
"Assess: diagnosis confirmation + mechanism + adherence",
"Manage via multidisciplinary team if available"
];
difficult.forEach((t, i) => {
s.addText([{ text: "β’ " + t }], { x: 5.2, y: 1.62 + i * 0.36, w: 4.4, h: 0.34, fontSize: 10, color: NAVY, fontFace: "Calibri", margin: 0 });
});
}
// βββ SLIDE 7: SELF-MANAGEMENT & FENO βββββββββββββββββββββββββββββββββββββββββ
{
let s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 5.625, fill: { color: LTBLUE }, line: { color: LTBLUE } });
addHeader(s, "Self-Management & Adjunct Strategies", "Sections 14 & 15 β Guided Self-Management | FeNO Monitoring");
// WAAP section
s.addShape(pres.ShapeType.rect, { x: 0.2, y: 1.2, w: 5.7, h: 0.4, fill: { color: NAVY }, line: { color: NAVY } });
s.addText("π Guided Asthma Self-Management (Good Practice 4.2)", { x: 0.3, y: 1.21, w: 5.5, h: 0.37, fontSize: 11, bold: true, color: WHITE, fontFace: "Calibri", margin: 0 });
const waap = [
{ h: "Written Asthma Action Plan (WAAP)", b: "Must be clear, updated, and provided to every patient/family. Guides independent medication adjustments." },
{ h: "Self-Monitoring", b: "Monitor symptoms AND/OR peak expiratory flow (PEF) regularly to detect early worsening." },
{ h: "Regular Physician Review", b: "Assess asthma control, adjust treatment, and check inhaler device skills at every visit." },
];
waap.forEach((item, i) => {
s.addText(item.h, { x: 0.4, y: 1.68 + i * 0.9, w: 5.4, h: 0.3, fontSize: 11, bold: true, color: TEAL, fontFace: "Calibri", margin: 0 });
s.addText(item.b, { x: 0.4, y: 1.98 + i * 0.9, w: 5.4, h: 0.5, fontSize: 10.5, color: NAVY, fontFace: "Calibri", margin: 0 });
});
// vertical divider
s.addShape(pres.ShapeType.line, { x: 6.2, y: 1.15, w: 0, h: 3.4, line: { color: TEAL, pt: 1.5 } });
// FeNO section
s.addShape(pres.ShapeType.rect, { x: 6.3, y: 1.2, w: 3.45, h: 0.4, fill: { color: "145A32" }, line: { color: "145A32" } });
s.addText("π¬ FeNO-Guided Treatment (Rec. 4h)", { x: 6.4, y: 1.21, w: 3.3, h: 0.37, fontSize: 11, bold: true, color: WHITE, fontFace: "Calibri", margin: 0 });
const feno = [
"FeNO = Fractional Exhaled Nitric Oxide",
"Weak recommendation (low certainty)",
"Helps reduce asthma exacerbation risk (RR 0.73)",
"23 RCTs, 2723 pediatric patients",
"Use as adjunct β not standalone tool",
"GINA 2021 has not adopted FeNO yet",
];
feno.forEach((t, i) => {
s.addText([{ text: "βΈ " + t }], { x: 6.35, y: 1.68 + i * 0.4, w: 3.35, h: 0.37, fontSize: 10, color: NAVY, fontFace: "Calibri", margin: 0 });
});
// bottom note
s.addShape(pres.ShapeType.rect, { x: 0.2, y: 4.85, w: 9.6, h: 0.38, fill: { color: NAVY }, line: { color: NAVY } });
s.addText("π Note: Sputum eosinophil count β insufficient evidence in children; no current recommendation (Cochrane 2017)", {
x: 0.3, y: 4.86, w: 9.4, h: 0.35, fontSize: 9.5, color: GRAY, fontFace: "Calibri", margin: 0, italic: true
});
}
// βββ SAVE βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ
pres.writeFile({ fileName: "/home/daytona/workspace/asthma-ppt/Asthma_LongTerm_Management_5.3.pptx" })
.then(() => console.log("β
PPT saved successfully!"))
.catch(e => { console.error("ERROR:", e); process.exit(1); });
cd /home/daytona/workspace/asthma-ppt && node build.js
Asthma LongTerm Management 5.3
Presentation Β· PPTX
"Principles of Long-Term Management in Asthma" with sub-topics listed (Pharmacologic Β· Step Therapy Β· Step-Down Β· Referral Β· Self-Management)
| Component | Details |
|---|---|
| π Pharmacologic Management | ICS, ICS-LABA, SABA (Key Q4) |
| πΏ Non-Pharmacologic Strategies | Trigger avoidance, prevention (Key Q 6,7,8) |
| π Self-Management & Education | Written Asthma Action Plan (Key Q5) |
| Key principle: Strong patient-family-provider partnership is essential. |